BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29798908)

  • 1. Ad5
    Uusi-Kerttula H; Davies JA; Thompson JM; Wongthida P; Evgin L; Shim KG; Bradshaw A; Baker AT; Rizkallah PJ; Jones R; Hanna L; Hudson E; Vile RG; Chester JD; Parker AL
    Clin Cancer Res; 2018 Sep; 24(17):4215-4224. PubMed ID: 29798908
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficient Intravenous Tumor Targeting Using the αvβ6 Integrin-Selective Precision Virotherapy Ad5
    Davies JA; Marlow G; Uusi-Kerttula HK; Seaton G; Piggott L; Badder LM; Clarkson RWE; Chester JD; Parker AL
    Viruses; 2021 May; 13(5):. PubMed ID: 34066836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery.
    Coughlan L; Vallath S; Saha A; Flak M; McNeish IA; Vassaux G; Marshall JF; Hart IR; Thomas GJ
    J Virol; 2009 Jul; 83(13):6416-28. PubMed ID: 19369326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5.
    Coughlan L; Vallath S; Gros A; Giménez-Alejandre M; Van Rooijen N; Thomas GJ; Baker AH; Cascalló M; Alemany R; Hart IR
    Hum Gene Ther; 2012 Sep; 23(9):960-79. PubMed ID: 22708837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells.
    Man YKS; Davies JA; Coughlan L; Pantelidou C; Blázquez-Moreno A; Marshall JF; Parker AL; Halldén G
    Mol Cancer Ther; 2018 Feb; 17(2):575-587. PubMed ID: 29367266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10.
    Bates EA; Davies JA; Váňová J; Nestić D; Meniel VS; Koushyar S; Cunliffe TG; Mundy RM; Moses E; Uusi-Kerttula HK; Baker AT; Cole DK; Majhen D; Rizkallah PJ; Phesse T; Chester JD; Parker AL
    Mol Ther Oncolytics; 2022 Jun; 25():43-56. PubMed ID: 35399606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.
    Takagi-Kimura M; Yamano T; Tamamoto A; Okamura N; Okamura H; Hashimoto-Tamaoki T; Tagawa M; Kasahara N; Kubo S
    Cancer Sci; 2013 Nov; 104(11):1433-9. PubMed ID: 23962292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses.
    Takagi-Kimura M; Yamano T; Tagawa M; Kubo S
    Cancer Gene Ther; 2014 Mar; 21(3):126-32. PubMed ID: 24577130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mosaic fiber adenovirus serotype 5 vector containing reovirus sigma 1 and adenovirus serotype 3 knob fibers increases transduction in an ovarian cancer ex vivo system via a coxsackie and adenovirus receptor-independent pathway.
    Tsuruta Y; Pereboeva L; Glasgow JN; Rein DT; Kawakami Y; Alvarez RD; Rocconi RP; Siegal GP; Dent P; Fisher PB; Curiel DT
    Clin Cancer Res; 2007 May; 13(9):2777-83. PubMed ID: 17473211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
    Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
    Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.
    Pesonen S; Diaconu I; Cerullo V; Escutenaire S; Raki M; Kangasniemi L; Nokisalmi P; Dotti G; Guse K; Laasonen L; Partanen K; Karli E; Haavisto E; Oksanen M; Karioja-Kallio A; Hannuksela P; Holm SL; Kauppinen S; Joensuu T; Kanerva A; Hemminki A
    Int J Cancer; 2012 Apr; 130(8):1937-47. PubMed ID: 21630267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model.
    Zhang Z; Krimmel J; Zhang Z; Hu Z; Seth P
    Hum Gene Ther; 2011 Sep; 22(9):1137-42. PubMed ID: 21480822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene.
    Grünwald GK; Vetter A; Klutz K; Willhauck MJ; Schwenk N; Senekowitsch-Schmidtke R; Schwaiger M; Zach C; Wagner E; Göke B; Holm PS; Ogris M; Spitzweg C
    J Nucl Med; 2013 Aug; 54(8):1450-7. PubMed ID: 23843567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of biodistribution of a fiber-chimeric, conditionally replication-competent (oncolytic) adenovirus in CD46 receptor transgenic mice.
    Ganesh S; Gonzalez-Edick M; Gibbons D; Waugh J; Van Roey M; Jooss K
    Hum Gene Ther; 2009 Oct; 20(10):1201-13. PubMed ID: 19572803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases.
    Shayakhmetov DM; Li ZY; Ni S; Lieber A
    Cancer Res; 2002 Feb; 62(4):1063-8. PubMed ID: 11861383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic adenovirus based on serotype 3.
    Hemminki O; Bauerschmitz G; Hemmi S; Lavilla-Alonso S; Diaconu I; Guse K; Koski A; Desmond RA; Lappalainen M; Kanerva A; Cerullo V; Pesonen S; Hemminki A
    Cancer Gene Ther; 2011 Apr; 18(4):288-96. PubMed ID: 21183947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.
    Ranki T; Kanerva A; Ristimäki A; Hakkarainen T; Särkioja M; Kangasniemi L; Raki M; Laakkonen P; Goodison S; Hemminki A
    Gene Ther; 2007 Jan; 14(1):58-67. PubMed ID: 16900223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells.
    Leja J; Yu D; Nilsson B; Gedda L; Zieba A; Hakkarainen T; Åkerström G; Öberg K; Giandomenico V; Essand M
    Gene Ther; 2011 Nov; 18(11):1052-62. PubMed ID: 21490682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo.
    Witlox AM; Van Beusechem VW; Molenaar B; Bras H; Schaap GR; Alemany R; Curiel DT; Pinedo HM; Wuisman PI; Gerritsen WR
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):61-7. PubMed ID: 14734452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation.
    Koizumi N; Mizuguchi H; Sakurai F; Yamaguchi T; Watanabe Y; Hayakawa T
    J Virol; 2003 Dec; 77(24):13062-72. PubMed ID: 14645563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.